KPRX (Kiora Pharmaceuticals) Total Operating Expense: $9.91 Mil (TTM As of Mar. 2026)


KPRX Kiora Pharmaceuticals Inc KPRX
32 GF Score
Price $2.61
! 3 Warning Signs
View Full Analysis

What is Kiora Pharmaceuticals Total Operating Expense?

Kiora Pharmaceuticals KPRX +0.77% 32 Total Operating Expense is $9.91 Mil as of Mar. 2026. GuruFocus rates KPRX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Kiora Pharmaceuticals's Total Operating Expense for the three months ended in Mar. 2026 was $2.50 Mil. Kiora Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $9.91 Mil.

Kiora Pharmaceuticals Total Operating Expense Related Terms

Kiora Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Kiora Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiora Pharmaceuticals Total Operating Expense Chart

Kiora Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.67 11.73 8.69 10.42 9.46

Kiora Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.06 2.26 2.52 2.63 2.50
KPRX
32GF Score
Kiora Pharmaceuticals Inc KPRX
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiora Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $9.91 Mil mean?
Kiora Pharmaceuticals (KPRX) has a Total Operating Expense of $9.91 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Kiora Pharmaceuticals and its competitors.
Is Kiora Pharmaceuticals' Total Operating Expense too high?
Kiora Pharmaceuticals' current Total Operating Expense is $9.91 Mil. Overall, Kiora Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Kiora Pharmaceuticals' Total Operating Expense compare to PHIO and PBM?
Kiora Pharmaceuticals' Total Operating Expense of $9.91 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Kiora Pharmaceuticals and its competitors. Kiora Pharmaceuticals's current Total Operating Expense is $9.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiora Pharmaceuticals stock overvalued right now?
Kiora Pharmaceuticals (KPRX) has a current Total Operating Expense of $9.91 Mil. The current Total Operating Expense is $9.91 Mil. Kiora Pharmaceuticals' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Kiora Pharmaceuticals (KPRX), the current Total Operating Expense is $9.91 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kiora Pharmaceuticals Business Description

Address 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
32GF Score

Get the complete analysis for KPRX

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.61
Price